Irhythm Technologies, Inc. (IRTC)

$89.95

+0.75

(+0.84%)▲

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Irhythm Technologies, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 111.43M → 124.60M (in $), with an average increase of 5.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -18.48M → -27.11M (in $), with an average decrease of 46.7% per quarter

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 22.5% return, outperforming this stock by 42.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 24.3% return, outperforming this stock by 75.0%

Performance

  • $88.30
    $90.88
    $89.95
    downward going graph

    1.83%

    Downside

    Day's Volatility :2.84%

    Upside

    1.02%

    downward going graph
  • $70.24
    $140.23
    $89.95
    downward going graph

    21.91%

    Downside

    52 Weeks Volatility :49.91%

    Upside

    35.86%

    downward going graph

Returns

PeriodIrhythm Technologies, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-10.41%
-1.3%
0.0%
6 Months
-15.22%
1.2%
0.0%
1 Year
-13.19%
-5.7%
-6.5%
3 Years
-50.66%
17.1%
-6.5%

Highlights

Market Capitalization
2.7B
Book Value
$7.18
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.44
PEG Ratio
0.0
Wall Street Target Price
113.3
Profit Margin
-22.19%
Operating Margin TTM
-19.75%
Return On Assets TTM
-13.54%
Return On Equity TTM
-45.71%
Revenue TTM
472.8M
Revenue Per Share TTM
15.56
Quarterly Revenue Growth YOY
20.0%
Gross Profit TTM
281.6M
EBITDA
-81.8M
Diluted Eps TTM
-3.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.38
EPS Estimate Next Year
-2.28
EPS Estimate Current Quarter
-0.66
EPS Estimate Next Quarter
-0.57

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Irhythm Technologies, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 25.96%

Current $89.95
Target $113.30

Company Financials

FY17Y/Y Change
Revenue
98.5M
↑ 53.75%
Net Income
-29.4M
↑ 40.75%
Net Profit Margin
-29.87%
↑ 2.75%
FY18Y/Y Change
Revenue
147.3M
↑ 49.52%
Net Income
-48.3M
↑ 64.11%
Net Profit Margin
-32.78%
↓ 2.91%
FY19Y/Y Change
Revenue
214.6M
↑ 45.66%
Net Income
-54.6M
↑ 13.02%
Net Profit Margin
-25.43%
↑ 7.35%
FY20Y/Y Change
Revenue
265.2M
↑ 23.59%
Net Income
-43.8M
↓ 19.68%
Net Profit Margin
-16.53%
↑ 8.9%
FY21Y/Y Change
Revenue
322.8M
↑ 21.74%
Net Income
-101.4M
↑ 131.26%
Net Profit Margin
-31.4%
↓ 14.87%
FY22Y/Y Change
Revenue
410.9M
↑ 27.29%
Net Income
-116.2M
↑ 14.6%
Net Profit Margin
-28.27%
↑ 3.13%
Q2 FY22Q/Q Change
Revenue
102.1M
↑ 10.47%
Net Income
-23.9M
↓ 52.78%
Net Profit Margin
-23.42%
↑ 31.36%
Q3 FY22Q/Q Change
Revenue
103.9M
↑ 1.79%
Net Income
-21.5M
↓ 10.24%
Net Profit Margin
-20.65%
↑ 2.77%
Q4 FY22Q/Q Change
Revenue
112.6M
↑ 8.42%
Net Income
-20.2M
↓ 5.84%
Net Profit Margin
-17.94%
↑ 2.71%
Q1 FY23Q/Q Change
Revenue
111.4M
↓ 1.05%
Net Income
-39.1M
↑ 93.63%
Net Profit Margin
-35.1%
↓ 17.16%
Q2 FY23Q/Q Change
Revenue
124.1M
↑ 11.39%
Net Income
-18.5M
↓ 52.74%
Net Profit Margin
-14.89%
↑ 20.21%
Q3 FY23Q/Q Change
Revenue
124.6M
↑ 0.38%
Net Income
-27.1M
↑ 46.72%
Net Profit Margin
-21.76%
↓ 6.87%
FY17Y/Y Change
Total Assets
133.1M
↓ 3.64%
Total Liabilities
53.6M
↑ 17.49%
FY18Y/Y Change
Total Assets
119.7M
↓ 10.08%
Total Liabilities
65.3M
↑ 21.87%
FY19Y/Y Change
Total Assets
306.2M
↑ 155.79%
Total Liabilities
170.8M
↑ 161.61%
FY20Y/Y Change
Total Assets
511.7M
↑ 67.12%
Total Liabilities
170.1M
↓ 0.4%
FY21Y/Y Change
Total Assets
463.0M
↓ 9.53%
Total Liabilities
183.5M
↑ 7.83%
FY22Y/Y Change
Total Assets
448.2M
↓ 3.18%
Total Liabilities
208.4M
↑ 13.6%
Q2 FY22Q/Q Change
Total Assets
435.7M
↑ 1.63%
Total Liabilities
191.0M
↑ 3.9%
Q3 FY22Q/Q Change
Total Assets
440.4M
↑ 1.08%
Total Liabilities
201.2M
↑ 5.3%
Q4 FY22Q/Q Change
Total Assets
448.2M
↑ 1.78%
Total Liabilities
208.4M
↑ 3.6%
Q1 FY23Q/Q Change
Total Assets
421.7M
↓ 5.92%
Total Liabilities
199.9M
↓ 4.1%
Q2 FY23Q/Q Change
Total Assets
429.5M
↑ 1.85%
Total Liabilities
205.6M
↑ 2.87%
Q3 FY23Q/Q Change
Total Assets
439.8M
↑ 2.39%
Total Liabilities
220.0M
↑ 6.99%
FY17Y/Y Change
Operating Cash Flow
-14.9M
↓ 10.45%
Investing Cash Flow
-34.7M
↓ 49.12%
Financing Cash Flow
6.5M
↓ 94.13%
FY18Y/Y Change
Operating Cash Flow
-29.1M
↑ 94.94%
Investing Cash Flow
34.1M
↓ 198.37%
Financing Cash Flow
6.3M
↓ 3.51%
FY19Y/Y Change
Operating Cash Flow
-21.9M
↓ 24.79%
Investing Cash Flow
-89.3M
↓ 361.67%
Financing Cash Flow
111.6M
↑ 1670.2%
FY20Y/Y Change
Operating Cash Flow
-13.8M
↓ 37.07%
Investing Cash Flow
-132.4M
↑ 48.3%
Financing Cash Flow
214.3M
↑ 92.08%
FY21Y/Y Change
Operating Cash Flow
-37.8M
↑ 174.39%
Investing Cash Flow
105.3M
↓ 179.51%
Financing Cash Flow
-28.6M
↓ 113.33%
FY22Y/Y Change
Operating Cash Flow
-23.0M
↓ 39.05%
Investing Cash Flow
-52.4M
↓ 149.81%
Financing Cash Flow
26.7M
↓ 193.49%
Q2 FY22Q/Q Change
Operating Cash Flow
-372.0K
↓ 99.04%
Investing Cash Flow
-431.0K
↓ 94.95%
Financing Cash Flow
7.3M
↓ 50.33%
Q3 FY22Q/Q Change
Operating Cash Flow
3.7M
↓ 1086.29%
Investing Cash Flow
-35.4M
↑ 8104.64%
Financing Cash Flow
1.7M
↓ 77.14%
Q4 FY22Q/Q Change
Operating Cash Flow
12.6M
↑ 242.76%
Investing Cash Flow
-8.1M
↓ 77.05%
Financing Cash Flow
3.1M
↑ 89.41%
Q1 FY23Q/Q Change
Operating Cash Flow
-30.8M
↓ 344.54%
Investing Cash Flow
3.8M
↓ 147.08%
Financing Cash Flow
905.0K
↓ 71.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.6M
↓ 85.13%
Investing Cash Flow
9.0M
↑ 135.84%
Financing Cash Flow
4.4M
↑ 384.09%

Technicals Summary

Sell

Neutral

Buy

Irhythm Technologies, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
10.15%
-15.22%
-13.19%
-50.66%
20.43%
Stryker Corporation
Stryker Corporation
7.57%
7.13%
25.17%
24.29%
72.88%
Dexcom, Inc.
Dexcom, Inc.
22.96%
-6.45%
0.05%
34.03%
264.69%
Boston Scientific Corp.
Boston Scientific Corp.
6.31%
9.22%
23.6%
63.15%
53.72%
Abbott Laboratories
Abbott Laboratories
10.4%
1.08%
-0.5%
-2.8%
46.69%
Medtronic Plc
Medtronic Plc
8.95%
-4.47%
1.52%
-29.74%
-17.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
NA
NA
0.0
-3.38
-0.46
-0.14
0.0
7.18
Stryker Corporation
Stryker Corporation
43.5
43.5
2.85
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
124.12
124.12
11.34
1.42
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
67.84
67.84
2.53
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
34.99
34.99
18.76
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.64
25.64
3.04
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
Buy
$2.7B
20.43%
NA
-22.19%
Stryker Corporation
Stryker Corporation
Buy
$111.6B
72.88%
43.5
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$43.1B
264.69%
124.12
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$81.5B
53.72%
67.84
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$178.6B
46.69%
34.99
12.92%
Medtronic Plc
Medtronic Plc
Buy
$105.1B
-17.1%
25.64
12.84%

Institutional Holdings

  • Vanguard Group Inc

    9.65%

  • Capital Research Global Investors

    7.75%

  • Sands Capital Management, LLC

    7.67%

  • BlackRock Inc

    7.61%

  • Artisan Partners Limited Partnership

    6.40%

  • AllianceBernstein L.P.

    4.49%

Corporate Announcements

  • Irhythm Technologies, Inc. Earnings

    Irhythm Technologies, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Organization
Irhythm Technologies, Inc.
Employees
1793
CEO
Mr. Quentin S. Blackford
Industry
Health Technology

Discover More

FAQs